Therefore, we studied the underlying mechanisms by which BMP9 treatment reduces inflammation in the hyperoxia-exposed lung by measuring the expression of important pro-inflammatory cytokines involved in BPD pathology, including MCP1 and IL6 (Wagenaar et al., 2004; Bhandari, 2014). The gene discussed is GDF2; the disease is bronchopulmonary dysplasia.